Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Benzinga02-13

Sanofi SA (NASDAQ:SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline. On Thursday, the French drugmaker with a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611150807?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2026-02-13 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611150807","market":"hk","top_or_hot":-1,"title":"Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors","media":"Benzinga","content":"<div>\n<p>Sanofi SA (NASDAQ:SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.\nOn Thursday, the French drugmaker with a ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-13 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi SA (NASDAQ:SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.\nOn Thursday, the French drugmaker with a ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","article_id":"2611150807","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Sanofi-SA.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50607808/sanofi-stock-near-52-week-low-as-leadership-shakeup-rattles-investors","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611150807","pubTimestamp":1770988980,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Sanofi shares drop after CEO exit and pipeline concerns grow, even as Dupixent sales jump in latest quarter.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","ISBC":"投资者银行","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4007":"制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4211":"区域性银行","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4217":"自存仓储房地产信托","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","REGN":"再生元制药公司","BK4585":"ETF&股票定投概念","SNYNF":"Sanofi","BK4139":"生物科技","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","SMA":"Smartstop Self Storage REIT Inc","SNY":"赛诺菲安万特"},"translate_title":"领导层变动令投资者不安，赛诺菲股价接近52周低点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"SNYNF":1.5,"SNY":1,"REGN":1,"SMA":1},"content_text":"Sanofi SA (NASDAQ:SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.\nOn Thursday, the French drugmaker with a market cap of around $113.6 billion closed 4.5% lower, closer to the lower end of the 52-week range of $44.62-$60.12.\nThe stock’s decline comes as the board announced the departure of CEO Paul Hudson, who will be succeeded by Belén Garijo, adding pressure as broader markets edged lower.\nOn Thursday, Sanofi’s board decided not to renew Paul Hudson’s mandate, with his last day as CEO set for February 17.\nBelén Garijo will take over after the Group’s Annual General Meeting on April 29, as the company aims to enhance its strategy and innovation capacity, particularly in Research & Development.\nIn the fourth quarter of 2025, Sanofi reported a 32.2% increase in sales of its top drug, Dupixent, totaling 4.2 billion euros.\nHowever, the company is grappling with declining vaccine sales, which dropped by 2.5% to 2 billion euros, and concerns over the future performance of Dupixent as it approaches loss of exclusivity.\nThe stock is currently trading 1.1% below its 20-day simple moving average (SMA) and 4% below its 100-day SMA, indicating a bearish trend in the short to medium term. Shares have decreased by 12.89% over the past 12 months and are currently positioned closer to their 52-week lows than highs.\nThe RSI is at 45.73, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum.\nSanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales.\nProfits for this immunology blockbuster drug are shared with Regeneron Pharmaceuticals Inc. (NASDAQ:REGN).\nThe recent leadership change is significant as it reflects the company’s need to address ongoing challenges in its drug pipeline and market performance. With the new CEO, Sanofi aims to strengthen its governance and innovation capacity, which will be crucial for its future growth.\nThe stock carries a Buy Rating with an average price forecast of $61.50. Recent analyst moves include:\nValuation Insight: While the stock trades at a fair P/E multiple, the strong consensus and rising estimates suggest analysts view the growth prospects as justification for the 32% upside to analyst targets.\nSNY Price Action: Sanofi shares were down 0.68% at $46.71 during premarket trading on Friday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611150807","isCrawlerRequest":true}